



Role of Probiotics in Health Improvement: Adaptations, Advantages and their Uses

Sumit Kumar^{1*}, Raj Kumar Pandey², Harshita Negi³, Prashant Sharma¹, Pooja Pandey¹, Yogesh Pandey¹ and Kritik Kumar¹

¹*Department of Molecular Biology and Genetic Engineering, College of Basic Sciences and Humanities, G. B. Pant University of Agriculture and Technology, Pantnagar, Uttarakhand, 263145, India.*

²*Department of Environmental Science, College of Basic Sciences and Humanities, G. B. Pant University of Agriculture and Technology, Pantnagar, Uttarakhand, 263145, India.*

³*Department of Genetics and Plant Breeding, College of Agriculture, G. B. Pant University of Agriculture and Technology, Pantnagar, Uttarakhand, 263145, India.*

Authors' contributions

This work was carried out in collaboration between all authors. All authors read and approved the final manuscript.

Article Information

DOI: 10.9734/AFSJ/2018/41026

Editor(s):

(1) Charalampos Proestos, Assistant Professor, Department of Chemistry, National and Kapodistrian University of Athens, Greece.

Reviewers:

(1) Lucian Ioniță, Romania.

(2) R. Prabha, Karnataka Veterinary, Animal and Fisheries Sciences University, Bangalore, India.

Complete Peer review History: <http://prh.sdiarticle3.com/review-history/24457>

Review Article

Received 16th February 2018

Accepted 24th April 2018

Published 4th May 2018

ABSTRACT

The probiotics especially lactic acid bacteria (LAB) are usually found in human mucous layers, dairy items and on some plant surfaces. These are assumed to be a basic part for nourishment generation and welfare conservation for human beings. There is an expanding fervor for these species to uncover the numerous possible medical advantages related with them. The activities of LAB's are depend on species or strain particular, and rely upon the measure of the number of beneficial microscopic organisms accessible in the gastrointestinal tract. Probiotics are having beneficial effect on human health therefore, with this paper, probiotics are acknowledged as characteristic way to safeguard nourishment and advance welfare. The paper present to survey the brief and current information regarding probiotics in the safeguarding of nourishments, their role in the gastrointestinal tract, and its medical advantages.

*Corresponding author: E-mail: sumitkumar4130@gmail.com;

Keywords: Probiotics; immunomodulation; lactic acid bacteria; gastrointestinal tract; health.

1. INTRODUCTION

Probiotics are live miniaturized scale life forms that managed in satisfactory amount, into gastrointestinal tract confer a health benefit to the host' (FAO/WHO, 2002) [1]. Probiotics are described as microorganisms that are acknowledged to give restorative favourable circumstances when used. The genera that contain the LAB are at its core *Lactobacillus*, *Leuconostoc*, *Pediococcus*, *Lactococcus*, and *Streptococcus*, and in addition the more fringe *Aerococcus*, *Carnobacterium*, *Enterococcus*, *Oenococcus*, *Porolactobacillus*, *Tetragenococcus*, *Vagococcus*, and *Weissella*. Lactic acid bacteria (LAB) are Gram-positive, non-sporulating, anaerobic or facultative high-impact cocci, which produce lactic acid after hydrolysis of starch [2]. Increasing number of studies demonstrate that the imbalance of such probiotics microscopic organisms in our stomach can be related the development of various diseases and illness. LAB's are either utilized as normally or chose starters in nourishment maturations where they perform fermentation of glucose containing molecules to the lactic acids [3]. Atomic organic techniques have expanded the quantity of genera incorporated into this gathering [3]. The administration utilizing these probiotics enhances nourishing estimation of sustenance items expanding the amount, accessibility, absorbability and assimilability of supplements. The basic part of probiotic lactic acid bacteria is the development of control of diet waste and pathogenic microorganisms [4]. They can improve lactose digestion, play a role in preventing and treating diarrhea and positively act on the immune system, helping the body to resist and fight infections. Common antimicrobial substances are considered as suitable other option to anti-infection treatment and a superior pharmaceutical approach [5]. The agriculture application of probiotics with respect to creature, fish, and plants generation has expanded bit by bit. Nonetheless, various vulnerabilities concerning innovative, microbiological viewpoints exist. [6,7].

2. ADAPTATION AND IMPORTANCE OF PROBIOTICS

Microbes are not all very bad. Over and over again one can relate microscopic organisms to germs and harmful microorganisms that resident micro flora without infection. The fact of the matter is the human body is comprised of billions

of microscopic organisms without them human of which we would not survive [8]. The expression "probiotics" identifies with sustenance's and wholesome supplements that contain these same "great" microscopic organisms found in the body [9,10,11]. The mammalian digestive tract is colonized by 100 trillions of microorganisms (called "microbiota" of the gut) that are fundamental for welfare of human health [12,13]. The move from soil and plants to the creature gut has three zones of genomic adjustment imperviousness to host obstructions, grip to intestinal cells, and maturation of a few substrates in the gut. The layer lipid organization is influenced by low pH and acidity salts [14,15].

Along with being found in nutritional supplements there are many foods that contain probiotics such as: miso, yogurt, fermented and unfermented milk, and various juices and soymilks. The importance of various probiotics and their brief uses for sustaining life are described in following [16,17,18].

1. Probiotics can reduce symptoms of diarrhea, especially when it is caused by taking certain antibiotics
2. Probiotics may prevent and treat yeast infections and urinary tract infections (UTI)
3. Probiotics may be an effective treatment for irritable bowel syndrome (IBS)
4. Probiotics can minimize the occurrence of bladder cancers
5. Probiotics can lessen the severity and duration of intestinal infections
6. Probiotics have been shown to reduce inflammation following colon surgery
7. Probiotics can be used to treat eczema and asthma in children.
8. Reduce the effect of the first attack of harmful compounds, instead of our cells, by their biofilm, therefore protects our digestive system.
9. Reduce the amount of food needed by our bodies due to the correct digestion and metabolism of any amount of food.
10. In some cases Probiotics could complement the deficiency in our genetic materials by helping us to borrow the products of their genes (such as in case of the lactose fermentation deficiency).
11. Probiotics promote health while they:
12. Remove the side effect of the pathogens and other or the harmful microbes.
13. Supply the useful bioproduct to body.

14. Reduce the jobs of our digestive system.
15. Can mature our sustenance and advance our wellbeing in the wide range of organ system.
16. Sometimes probiotics working as Specific anti-toxic medicines, where they are required to be influenced seriously, in day to day life [19].

Here we should highlight that, Probiotics or anything in our lives should not exceed from a certain limit and should be used wisely to give the best expected results for human body [20,21,22].

Traditional *Chinese medicine* (TCM) are naturally known about the advantages of Probiotics for quite a long time, and regularly consolidate their utilization with conventional TCM herbology medications or modalities, for example, needle therapy. There is mounting proof for the utilization of such complimentary medicines. [23,24,25]. A current report distributed by two American doctors in the Journal of the American Academy of Asthma and Immunology reasoned that regulating the Chinese therapeutic herbs Gan Cao, Ku Shen, and Ling Zhi, alongside probiotics positively affected Asthma in kids [26,27,28,29].

3. NANOENCAPSULATION AND HEALTH BENEFITS OF PROBIOTICS

Nanoencapsulation is the biggest part of the nanotechnology prospective in the food industry based on nano technology [30,5]. Nanotechnology can reduce the amount of active ingredients Nanoencapsulation can be used to design the probiotic bacteria preparation of delivery at the specific part of the gastrointestinal tract [31,32,33,34]. Encapsulated forms of ingredients accomplish longer shelf life of realistic usability of the item [35,36,37,38]. Nanoencapsulation is desirable to create designer probiotic bacterial arrangements that could be conveyed to specific parts of the gastrointestinal tract where they collaborate with particular receptors. A starch-like nanoparticle can stop lipids from oxidizing and therefore improve the stability of oil-in-water emulsions [39,40,41,42].

Nanoencapsulation of gainful probiotics microorganisms is advantageous as that focused on site particular of the gastro-intestinal tract for proper working of probiotics bacteria [26,43,44,45,46]. Furthermore, these nanoencapsulated creator bacterial

arrangements can be utilized as a part for immunization planning too to enhance the immunity (29) [47,48].

Probiotics can turn many health benefits to the human, animals, and plant. Some of these advantages have been very much achieved and built up, while the others have demonstrated a promising potential, with human examinations required to substantiate these cases [49]. The advantages of probiotic microscopic organisms are exceptionally strain particular; hence, there is no general strain that would give all proposed benefits and not all strains of similar species are successful against characterized wellbeing conditions [49]. The objective of probiotic food items is to have up to 10^7 CFU/g towards the finish of their time span of usability [50,51]. At present, a few very much described strains of Lactobacilli and Bifidobacteria are accessible for human use to decrease the danger of gastrointestinal (GI) diseases [47]. However probiotic lactic acid bacteria (LAB) must pass through a several growth inhibitor to guarantee they achieve the satisfactory numbers in the objective area to evoke their impact. The three significant areas of the human gastrointestinal tract are the stomach is essentially possessed by high-impact gram-positive microorganisms ($<10^3$ CFU/g) [52,53,54,55,56]. The small digestive tract is occupied by the genera *Lactobacillus*, *Bifidobacterium*, *Bacteroides*, and *Streptococcus* ($10^3 - 10^4$ CFU/g). Also, the large intestine is populated by the genera *Bacteroides*, *Fusobacterium*, *Lactobacillus*, *Bifidobacterium*, and *Eubacterium* in huge numbers ($10^{11} - 10^{12}$ CFU/g). There are many reports of the probiotic impact of LAB [57,58,59,60,61]. A list of the major classes of probiotic bacteria listed in the following Table 1 [62,63].

Probiotics probably apply a double impact, forestalling the intestinal colonization with pathogen microorganisms [26,8,64]. Or connecting with the gut-related lymphoid tissue (GALT) to forestall provocative reactions and advance a condition of resistance to themselves and potentially to sustenances [65]. The helpful impacts of probiotics are regularly dissimilar and strain-particular [66]. A few animal categories presented valuable impacts, for example, the treatment of intense looseness of the bowels related with rotavirus [67], ulcerative colitis [68,69]. *Clostridium difficile*-related loose bowels [70]. and *Helicobacter pylori* disease [71,72,73]. Probiotics which are traditional idea in the human food have been extended to animals by

developing fortified feed with intestinal microbiota to benefit the animals. Different impacts are on liver infection, hypersensitivity, or, then again AIDS. Previous studies [66,74,75]. Revealed a reduction of necrotizing enterocolitis in preterm newborn children if *Lactobacillus* and *Bifidobacterium* colonize the digestive system, or if bosom drain instead of recipe is utilized. Gewolb et al. [76], revealed that untimely babies conveyed by caesarian segment did not endure the ordinary procedure by which LAB are ingested by means of vaginal birth and spread by the mother's drain, enabling pathogens to build inside the early digestive tract [77,78]. There is no consistency in the sort or mix of probiotics utilized. In various reviews where just a single probiotic strain was utilized there was not huge factual change in the rate of necrotizing enterocolitis; yet when at least two probiotic

strains were utilized as a part of blend, a diminish in the occurrence was watched [79,80]. Furthermore, Studies recommend that probiotics can enhance the invulnerable framework capacities, for example, by diminishing upper respiratory tract infection (in grown-ups also), and by supplying the requirement for anti-infection agents. So also, de Silva et al. [81,82] played out a precise investigation of approaches to avert the improvement of nourishment hypersensitivity in youngsters and grown-ups. Among a few factors, probiotics did not appear to be defensive in babies at high or typical hazard [83]. done a learn about the adequacy and wellbeing of probiotics use in immunocompromised disease patients, as case reports distinguished a *Lactobacillus* strain utilized as a part of probiotic treatment to be required with bacteraemia and sepsis [84,85].

Table 1. Families of probiotic microorganisms

Lactobacilli	Bifidobacteria	Other microorganisms
<i>Lactobacillus acidophilus</i>	<i>Bifidobacterium bifidum</i>	<i>Bacillus clausii</i>
<i>L. acidophilus</i> La-1	<i>B. breve</i>	<i>Escherichia coli</i> Nissle 1917
<i>L. casei</i>	<i>B. infantis</i>	<i>Saccharomyces cerevisiae</i> (<i>boulardi</i>)
<i>L. reuteri</i>	<i>B. longum</i>	
<i>L. rhamnosus</i>		
<i>L. bulgaricus</i>		
<i>L. plantarum</i>		




Fig. 1. Probiotics health beneficial application [86,87]

At finally lactic acid bacteria (LAB) are great possibility to create novel oral vectors for mucosal conveyance systems, to cure the diseases and improve health benefits, more over for lessened pathogens constituting alluring other options to lessened pathogens. Bermidez-Humarán et al. [88,89]. Have focused in improvement of hereditary of *Lactobacillus lactis* for such improvements [44,90,91].

4. FRUIT / VEGETABLE-BASED AND OTHER PROBIOTICS PRODUCTS

The fruits and vegetables are rich in the functional food components such as sugar amino acids. Fruit juices are already being used as carriers of probiotic bacteria in a limited amount [92]. Probiotic microorganisms found in such organic product items give a promising territory to investigation, particularly due of their capacity to endure acidic environment [93,94,95,96,97].

Yogurt and milk are the most well-known vehicles of probiotics among dairy items. In any case, alternative carrier, for example, cheese seems to be appropriate. Cheeses have various points of interest over yogurt and matured milks since they have higher pH (6.57–6.85) and buffering limit, , high vitality, more strong consistency, generally higher fat substance, and longer shelf life [83,84].

5. TECHNIQUES FOR ANALYSIS AND QUANTIFICATION OF PROBIOTICS BOTH CULTURE AND NON CULTURE (METAGENOMIC) TECHNIQUES ARE BEING USED

In situ techniques are accessible certain dairy items, for example, from the International

Organization of Standardization (ISO) in regards to count models for *Lactobacillus acidophilus* (ISO 20128/IDF 192:2006) and *Bifidobacterium* (ISO 29981/IDF 220:2010) .No single culture-based procedure is appropriate to all probiotic microorganisms [98], due to the inconsistency among species or strains. The selective factors influencing the viability of seventeen LAB and probiotic strains were evaluated in the present study in order to optimize plating methodology. Latest new culture-free techniques have been used to precisely identify probiotic strains in view of practicality [99,100,101,102]. These strategies either utilize colours to separate live and dead cells, measure the cell layer uprightness, or describe some part of metabolic movement (blend of nucleic acids, or breath). Confocal filtering laser microscopy builds de affectability and empowers the perception of subsurface structures of nourishments in situ [103,104]. The utilization of this system in blend with the quantitative polymerase chain response (qPCR) has been utilized for the identification of probiotic strains in cheese cheddar [105,106]. Detection of nucleic acid sequence (DNA, mRNA and rRNA) is a molecular technique that can be connected to bacterial count. Most molecular investigations target amplification of nucleic acid to boost affectability. DNA amplification by PCR was researched for enumeration of live microscopic organisms in light of the suspicion that DNA would be degraded more quickly after cell damage than other cell components and that in place DNA sequence would demonstrate cell suitability [61,107,108]. Ethidium monoazide PCR or propidium monoazide PCR is developing procedures that farthest point identification to live cells and can likewise be alluded to as feasibility PCR (vPCR) [109,110]. Cell sorting techniques (Coulter counters and stream cytometry) were

Table 2. The Fruit and Vegetable-based probiotic product [110]

Category	Product
Fruit and vegetable based	Cranberry, pineapple, and orange juices
	Ginger juice Grape and passion fruit juices Cabbage juice
	Carrot juice
	Noni juice
	Onion
	Probiotic banana puree
	Nonfermented fruit juice beverages Blackcurrant juice
	Vegetable-based drinks
	Fermented banana pulp
	Fermented banana Beets-based drink
	Tomato-based drink
	Many dried fruits Green coconut water
	Peanut milk




Fig. 2. Culture and non-culture based techniques to assess viability of probiotic strains [9,10,11]

initially created for numbering red blood cells; however they have been redesigned and adjusted to break down substantially cell lifter is a tool for harvesting stem cell, for example, microorganisms [98]. Alternative methods, such as fluorescent in situ hybridization (FISH), nucleic acid amplification techniques such as real-time quantitative PCR (RT-qPCR or qPCR), reverse transcriptase (RT-PCR), propidium monoazide-PCR, and cell sorting techniques such as flow cytometry (FC)/fluorescent activated cell sorting (FACS) offer the potential to enumerate both culturable and Viable but nonculturable (VBNC) bacteria [108].

Stream cytometry permits the investigation of an expansive number of cells at once, recording, for every occasion (microscopic organisms) a few parameters [67,111,112]. Diverse fluorescent tests can be connected to analyze the physiological attributes of probiotic living cells, such cell film respectability, intracellular chemical action, cytoplasmic pH, and layer potential [113,114].

6. CONCLUSIONS AND FUTURE PERSPECTIVES

The desires of probiotic microscopic organisms have turned into the most requesting for any

bacterial gathering. Probiotics have turned into an essential component to ordinary well being sustenance items, and their worldwide market is assessed previously US\$28.8 billion by 2015 [55]. Purchasers are exceptionally worried of concoction additives and handled nourishments, despite the fact that it gives a review of well being and nourishment assorted qualities never observed. Be that as it may, shoppers acknowledge effortlessly lactic acid bacteria (LAB) as a characteristic approach to save nourishment and advance their well being. In the most recent decade the enthusiasm for bacteriocins created by lactic acid bacteria (LAB) has expanded drastically [40,34,43]. The applicability of probiotics in food items depends all in all on factors like water action, handling and capacity temperature, timeframe of realistic usability, oxygen content, pH, mechanical pressure, salt substance, also, substance of other destructive or essential ingredients. In any case, there are a wide range of sorts of pathogens in nature, so the particular utilization of a specific bacteriocin can't dispense with every single bacterial pathogen. Lately, the expanded number of multi-medication safe pathogens has turned into a difficult issue. The improvement of another era of antimicrobial operators is a troublesome assignment. Biotechnological techniques are been connected to make new or multi-functional bacteriocins, so they could be broadly utilized as a part of sustenance, creature cultivation, and prescription. Both conventional cell culture strategies, and in addition the option systems (coordinate imaging and visual list, nucleic corrosive based specification techniques, and stream cytometry and cell sorting), offer points of interest and confinements for specifying probiotic microorganisms [98]. The new strategies and methods indicate significant guarantee for evaluating live microorganisms in various metabolic states. In any case, the probiotic viability can't be anticipated exclusively on the premise of reasonable cells. [115,116,117]. Probiotic organisms are crucial for the maintenance of balance of human intestinal microbiota [118,119]. Numerous scientific reports confirm their positive effect in the host. Probiotics ingredients are one of the largest functional food. Resulting studies are expected to assess the well being advancing movement of probiotic microscopic organisms.

ACKNOWLEDGEMENT

The authors are thankful to Department of Molecular Biology & Genetic Engineering

(MBGE), CBSH, GBPUAT, Pantnagar, Uttarakhand for providing necessary facilities for preparation of this review article.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Report of a Joint FAO/WHO Working Group on Drafting Guidelines for the Evaluation of Probiotics in Food. London, Ontario, Canada: 2002. April, May. Guidelines for evaluation of probiotics in food. [Ref list]
2. Hayek SA, Ibrahim SA. Current limitations and challenges with lactic acid bacteria: A review. Food and Nutrition Sciences, (2013) 4, 73-87. Available:<http://dx.doi.org/10.4236/fns.2013.411A010>.
3. Von Wright A, Axelsson L. Lactic acid bacteria: An introduction. In: Lahtinen, S., Ouwehand, A.C., Salminen, S. and von Wright, A., Eds., Lactic acid bacteria: Microbiological and functional aspects, 4th Edition, Taylor & Francis Group LLC, CRC Press, Boca Raton. 2012;1-16.
4. Orla-Jensen S. The latic acid bacteria. Andr. Fred. Host and Son, Copenhagen; 1919.
5. Bhupinder S Sekhon. Food nanotechnology – An overview, Nanotechnology, Science and Applications. 2010;3:1–15.
6. Corfield AP, Myerscough N, Longman R, Sylvester P, Arul S, Pignatelli M. Mucins and mucosal protection in the gastrointestinal tract. New Prospects for Mucins in the Pathology of Gastrointestinal Disease. Gut. 2000;47:589-594. Available:<http://dx.doi.org/10.1136/gut.47.4.589>
7. Moal VL-L, Servin AL. The front line on enteric host defence against unwelcome intrusion of harmful microorganisms: Mucins, Antimicrobial Peptides and Microbiota. Clinical Microbiology Reviews. 2006;19:315-337. Available:<http://dx.doi.org/10.1128/CMR.19.2.315-337.2006>
8. Coconnier MH, Lievin V, Lorrot M, Servin AL. Antagonistic Activity of *Lactobacillus acidophilus* LB against *Intracellular*

- salmonella, enterica* Serovar *Typhimurium* Infecting human enterocyte-like Caco-2/TC-7 cells. Applied and Environmental Microbiology. 2000;66:1152-1157. Available:<http://dx.doi.org/10.1128/AEM.66.3.1152-1157.2000>
9. Fittipaldi M, Nocker A, Codony F. Progress in understanding preferential detection of live cells using viability dyes in combination with DNA amplification. Journal of Microbiological Methods. 2012;91:276-289.
 10. Chen S, Cao Y, Ferguson LR, Shu Q, Garg S. Flow Cytometric Assessment of the Protectants for Enhanced in Vitro Survival of Probiotic Lactic Acid Bacteria through Simulated Human Gastro-Intestinal Stresses. Applied Microbiology and Biotechnology. 2012;95:345-356.
 11. FAO/WHO (2002) Joint FAO/WHO Working Group Report on Drafting Guidelines for the Evaluation of Probiotics in Food. London, Ontario, Canada, April 30 and May 1. Available:http://www.who.int/foodsafety/publications/fs_management/probiotics2/en/
 12. Morelli L, Calleagri ML, Vogensen FK, von Wright A. Genetics of lactic acid bacteria. In: Lahtinen, S., Ouwehand, A.C., Salminen, S. and von Wright, A., Eds., lactic acid bacteria: Microbiological and functional aspects, 4th Edition, Taylor & Francis Group LLC, CRC Press, Boca Raton. 2012;17-38.
 13. Hooper LV, Macpherson AJ. Immune Adaptations that maintain homeostasis with the intestinal microbiota. Nature Reviews Immunology. 2010;10:159-169. Available:<http://dx.doi.org/10.1038/nri2710>.
 14. Kamada N, Seo S-U, Chen GY, Núñez G. Role of the gut microbiota in immunity and inflammatory disease. Nature Reviews Immunology. 2013;13:321-335. Available:<http://dx.doi.org/10.1038/nri3430>
 15. Lebeer S, Vanderleyden J, De Keersmaecker SC. Genes and molecules of lactobacilli supporting probiotic action. Microbiology and Molecular Biology Reviews. 2008;72:728-764. Available:<http://dx.doi.org/10.1128/MMBR.00017-08>
 16. Besselink MG, van Santvoort HC, Buskens E, Boermeester MA, van Goor H, Timmerman HM, et al. Probiotic prophylaxis in predicted severe acute pancreatitis: A randomised, double-blind, placebo-controlled trial. The Lancet. 2008; 371:651-659. Available:[http://dx.doi.org/10.1016/S0140-6736\(08\)60207-x](http://dx.doi.org/10.1016/S0140-6736(08)60207-x)
 17. Fuller R. Probiotics in human medicine. Gut. 1991;32:439-442.
 18. Fuller R. Probiotics, The scientific basis. Chapman & Hall, London, New York, Tokyo, Melbourne, Madras. 1992;398.
 19. Coombes JL, Maloy KJ. Control of intestinal homeostasis by regulatory T cells and dendritic cells. Seminars in Immunology. 2007;19:116-126. Available:<http://dx.doi.org/10.1016/j.smim.2007.01.001>
 20. Fayol-Messaoudi D, Berger CN, Coconnier-Polter M-H, Moal VL-L, Servin AL. pH-, lactic acid and non-lactic acid-dependent activities of *Probiotic Lactobacilli* against *Salmonella enterica* Serovar *Typhimurium*. Applied and Environmental Microbiology. 2005;71: 6008-6013. Available:<http://dx.doi.org/10.1128/AEM.71.10.6008-6013.2005>
 21. Available:<https://www.pacificcollege.edu/news/blog/2014/10/21/importance-probiotics>
 22. Salminen S, von Wright A, Morelli L, Marteau P, Brassart D, de Vos WM, Fondeñ R, Saxelin M, Collins K, Mogensen G, Birkeland SE, Mattila-Sandholm T. Demonstration of safety of Probiotics – a review. Int. J. Food Micro Biol. 1998;44:93–106.
 23. Lakhdari O, Cultrone A, Tap J, Gloux K, Bernard F, Ehrlich SD, Lefevre F, Dore J, Blottiere HM. Functional metagenomics: A high throughput screening method to decipher microbiota-driven nf-kappab modulation in the human gut. PLoS ONE, 2010;5:e13092. Available:<http://dx.doi.org/10.1371/journal.pone.0013092>
 24. Meijerink M, Wells JM. Probiotic modulation of dendritic cells and T Cell responses in the intestine. Beneficial Microbes. 2010;1:317-216. Available:<http://dx.doi.org/10.3920/BM2010.0029>
 25. Sazawal S, Hiremath G, Dhingra U, Malik P, Deb S, Black RE. Efficacy of probiotics in prevention of acute diarrhoea: A meta-analysis of masked, randomised, placebo-controlled trials. Lancet Infectious Diseases. 2006;6:374-382. Available:[http://dx.doi.org/10.1016/S1473-3099\(06\)70495-9](http://dx.doi.org/10.1016/S1473-3099(06)70495-9)

26. Coconier MH, Bernet MF, Kerneis S, Chauviere G, Fourniat J, Sercin AL. Inhibition of adhesion of enteroinvasive pathogens to human intestinal Caco-2 cells by *Lactobacillus acidophilus* strain LB decreases bacterial invasion. *FEMS Microbiology Letters*. 1993;110:299-305. Available:<http://dx.doi.org/10.1111/j.1574-6968.1993.tb06339.x>
27. Cleveland J, Montville TJ, Nes IF, Chikindas ML. Bacteriocins: Safe, natural antimicrobials for food preservation. *International Journal of Food Microbiology*. 2001;71:1-20. Available:[http://dx.doi.org/10.1016/S0168-1605\(01\)00560-8](http://dx.doi.org/10.1016/S0168-1605(01)00560-8)
28. Bernbom N, Licht TR, Brogren CH, Jelle B, Johansen AH, Badiola I, Vogensen FK, Norrung B. Effects of *Lactococcus lactis* on composition of intestinal microbiota: Role of nisin. *Applied and Environmental Microbiology*. 2006;72:239-244. Available:<http://dx.doi.org/10.1128/AEM.72.1.239-244.2006>
29. Deitch E, Specian E, Steffen E, Berg R. Translocation of *Lactobacillus murinus* from the gastrointestinal tract. *Current Microbiology*. 1990;20:177-184. Available:<http://dx.doi.org/10.1007/BF02091994>
30. Anonymous. NCBI taxonomy browser. E. J. Quinto et al. 1770; 2014. Available:<http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi>.
31. Gopal PK, Prasad J, Smart J, Gill HS. *In Vitro* adherence properties of *Lactobacillus rhamnosus* DR20 and *Bifidobacterium lactis* DR10 strains and their antagonistic activity against an enterotoxigenic *Escherichia coli*. *International Journal of Food Microbiology*. 2001;67:207-216. Available:[http://dx.doi.org/10.1016/S0168-1605\(01\)00440-8](http://dx.doi.org/10.1016/S0168-1605(01)00440-8)
32. Hudault S, Lievin V, Bernet-Camard MF, Servin AL. Antagonistic activity exerted *in Vitro* and *in Vivo* by *Lactobacillus casei* (Strain GG) against *Salmonella typhimurium* C5 infection. *Applied and Environmental Microbiology*. 1997;63: 513-518.
33. Altenhoefer A, Oswald S, Sonnenborn U, Enders C, Schulze J, Hacker J, Oelschlaeger TA. The probiotic *Escherichia coli* strain Nissle 1917 interferes with invasion of human intestinal epithelial cells by different enteroinvasive bacterial pathogens. *FEMS Immunology and Medical Microbiology*. 2004;40: 223-229. Available:[http://dx.doi.org/10.1016/S0928-8244\(03\)00368-7](http://dx.doi.org/10.1016/S0928-8244(03)00368-7)
34. Hoover G, Steenson LR. Bacteriocins of lactic acid bacteria. Academic Press Inc., New York; 1993.
35. Kwon HK, Lee CG, So JS, Chae CS, Hwang JS, Sahoo A, Nam JH, Rhee JH, Hwang KC, Im SH. Generation of regulatory dendritic cells and CD4+ Foxp3+ T cells by probiotics administration suppresses immune disorders. *Proceedings of the National Academy of Sciences of the United States of America*. 2010;107:2159-2164. Available:<http://dx.doi.org/10.1073/pnas.0904055107>
36. Pretzer G, Snel J, Molenaar D, Wiersma A, Bron PA, Lambert J, de Vos WM, van der Meer R, Smits MA, Kleerebezem M. Biodiversity-based identification and functional characterization of the mannose-specific adhesin of *Lactobacillus plantarum*. *Journal of Bacteriology*. 2005;187:6128-6136. Available:<http://dx.doi.org/10.1128/JB.187.17.6128-6136.2005>
37. Denou E, Pridmore RD, Berger B, Panoff JM, Arigoni F, Brussow H. Identification of genes associated with the long-gut-persistence phenotype of the Probiotic *Lactobacillus johnsonii* strain NCC533 using a combination of genomics and transcriptome analysis. *Journal of Bacteriology*. 2008;190:3161-3168.
38. Meijerink M, van Hemert S, Taverne N, Wels M, de Vos P, Bron PA, Savelkoul HF, van Bilsen J, Kleerebezem M, Wells JM. Identification of genetic loci in *Lactobacillus plantarum* that modulate the immune response of dendritic cells using comparative genome hybridization. *PLoS ONE*. 2010P;5:e10632. Available:<http://dx.doi.org/10.1371/journal.pone.0010632>
39. Boudeau J, Glasser AL, Julien S, Colombel JF, Darfeuille-Michaud A. Inhibitory effect of probiotic E. J. Quinto et al. 1771 *Escherichia coli* strain Nissle 1917 on adhesion to and invasion of intestinal epithelial cells by adherent invasive *E. coli* strains isolated from patients with crohn's disease. *Alimentary Pharmacology & Therapeutics*. 2003;18:45-56. Available:<http://dx.doi.org/10.1046/j.1365-2036.2003.01638.x>

40. Montville TJ, Winkowski K. Biologically based preservation systems and probiotic bacteria. In: Doyle, M.P., Beuchat, L.R. and Montville, T.J., Eds., Food Microbiology: Fundamentals and Frontiers, ASM, Washington DC; 1997.
41. Vidhyalakshmi R, Bhakayaraj R, Subhasree RS. Encapsulation “The future of probiotics” – A review. Adv Biol Res. 2009; 3–4:6–103.
42. Wang X, Jiang Y, Wang YW, Huang MT, Ho CT, Huang Q. Enhancing antiinflammation activity of curcumin through O/W nanoemulsions. Food Chem. 2008;108(2):419–424. 31. Kim KD, Han DN, Lee JB, Kim HT. Formation and characterization of Ag-deposited TiO₂ nanoparticles by chemical reduction method. Scripta Materialia. 2006;54:143–146.
43. Klaenhammer TR. Genetics of bacteriocins produced by lactic acid bacteria. FEMS Microbiology Reviews. 1993;12:39-86. Available:<http://dx.doi.org/10.1111/j.1574-6976.1993.tb00012.x>
44. Yang S-C, Lin C-H, Sung CT, Fang J-Y. Antibacterial activities of bacteriocins: Application in Foods and Pharmaceuticals. Frontiers in Microbiology. 2014;5:1-10. Available:<http://dx.doi.org/10.3389/fmicb.2014.00241>
45. Bogunovic M, Ginhoux F, Helft J, Shang L, Hashimoto D, Greter M, Liu K, Jakubzick C, Ingersoll MA, Leboeuf M, Stanley ER, Nussenzweig M, Lira SA, Randolph GJ, Merad M. Origin of the Lamina Propria Dendritic Cell Network. Immunity. 2009;31: 513-525. Available:<http://dx.doi.org/10.1016/j.immuni.2009.08.010>
46. Varol C, Vallon-Eberhard A, Elinav E, Aychek T, Shapira Y, Luche H, Fehling HJ, Hardt WD, Shakhar G, Jung S. Intestinal lamina propria dendritic cell subsets have different origin and functions. Immunity, 2009;31:502-512. Available:<http://dx.doi.org/10.1016/j.immuni.2009.06.025>
47. Salminen S, Ouwenhand A, Benno Y, Lee YK. Probiotics: How should they be defined? Trends in Food Science and Technology. 1999;10:107-110. Available:[http://dx.doi.org/10.1016/S0924-2244\(99\)00027-8](http://dx.doi.org/10.1016/S0924-2244(99)00027-8)
48. Chikindas ML. Probiotics and antimicrobial peptides: The creatures’ and substances’ future in the twentyfirst century: An opinion letter. Probiotics and Antimicrobial Proteins. 2014;6:69-72. Available:<http://dx.doi.org/10.1007/s12602-014-9161-7>
49. Coconnier MH, Lievin V, Bernet-Camard MF, Hudault S, Servin AL. Antibacterial effect of the adhering human lactobacillus acidophilus strain LB. Antimicrobial Agents and Chemotherapy. 1997;41:1046-1052.
50. Kobayashi N, Saito T, Uematsu T, Kishi K., Toba M, Kohda N, Suzuki T. Oral administration of heat-killed *Lactobacillus pentosus* strain b240 augments protection against influenza virus infection in mice. International Immunopharmacology. 2011;11:199-203. Available:<http://dx.doi.org/10.1016/j.intimp.2010.11.019>
51. Corcoran BM, Ross RP, Fitzgerald GF, Dockery P, Stanton C. Enhanced survival of GroESL-overproducing *Lactobacillus paracasei* NFBC 338 under stressful conditions induced by drying. Applied and Environmental Microbiology. 2006;72: 5104-5107. Available:<http://dx.doi.org/10.1128/AEM.02626-05>
52. Savage D. Microbiology of the gastrointestinal tract. Annual Review of Microbiology. 1977;31:107-133. Available:<http://dx.doi.org/10.1146/annurev.mi.31.100177.000543>
53. McCracken VJ, Lorenz RG. The gastrointestinal ecosystem: Aprecarious alliance among epithelium, immunity and microbiota. Cellular Microbiology. 2001;3:1-11. Available:<http://dx.doi.org/10.1046/j.1462-5822.2001.00090.x>
54. Simon GL, Gorbach SL. Intestinal flora in health and disease. Gastroenterology. 1984;86:174-193.
55. Mills S, Stanton C, Fitzgerald GF, Ross, RP. Enhancing the stress responses of probiotics for a lifestyle from gut to product and back again. Microbial Cell Factories. 2011;10:S19. Available:<http://dx.doi.org/10.1186/1475-2859-10-S1-S19>
56. Dethlefsen L, Eckburg PB, Bik EM, Relman DA. Assembly of the human intestinal microbiota. Trends in Ecology & Evolution. 2006;21:517-523. Available:<http://dx.doi.org/10.1016/j.tree.2006.06.013>

57. Klaenhammer TR, Barrangou R, Buck BL, Azcarate-Peril MA, Altermann E. Genomic features of lactic acid bacteria effecting bioprocessing and health. *FEMS Microbiology Reviews*. 2005;29:393-409. Available:<http://dx.doi.org/10.1016/j.fmrre.2005.04.007>
58. Mack DR, Michail S, Wei S, McDougall L, Hollingsworth MA. Probiotics inhibit enteropathogenic *E. coli* adherence *in vitro* by inducing intestinal mucin gene expression. *American Journal of Physiology*. 1999;276:G941-G950.
59. Mack DR, Ahrne S, Hyde L, Wei S, Hollingsworth MA. Extracellular MUC3 mucin secretion follows adherence of lactobacillus strains to intestinal epithelial cells *in Vitro*. *Gut*. 2003;52:827-833. Available:<http://dx.doi.org/10.1136/gut.52.6.827>
60. Montville TJ, Matthews K. *Food Microbiology: An introduction*. ASM Press, Washington DC; 2005.
61. Ammor MS, Flórez AB, van Hoek AH, de Los Reyes-Gavilán CG, Aarts HJ, Margolles A, Mayo B. Molecular characterization of intrinsic and acquired antibiotic resistance in lactic acid bacteria and bifidobacteria. *Journal of Molecular Microbiology and Biotechnology*. 2008;14: 6-15. Available:<http://dx.doi.org/10.1159/000106077>
62. Servin AL. Antagonistic activities of lactobacilli and bifidobacteria against microbial pathogens. *FEMS Microbiology Reviews*. 2004;28:405-440. Available:<http://dx.doi.org/10.1016/j.femsre.2004.01.003>
63. Bernet-Camard MF, Lievin V, Brassart D, Neeser JR, Servin AL, Hudault S. The Human lactobacillus acidophilus strain LA1 secretes a nonbacteriocin antibacterial substance(s) active *in Vitro* and *in Vivo*. *Applied and Environmental Microbiology*. 1997;63:2747-2753.
64. Arvola T, Laiho K, Torkkeli S, Mykkanen H, Salminen S, Maunula L, Isolauri E. Prophylactic lactobacillus gg reduces antibiotic-associated diarrhea in children with respiratory infections: A Randomized Study. *Pediatrics*. 1999;104:e64. Available:<http://dx.doi.org/10.1542/peds.104.5.e64>
65. Turcanu V, Lack G. Molecular and immunological responses to food. In: Maleki, S.J., Burks, A.W. and Helm, R.M., Eds., *Food Allergy*, ASM Press, Washington DC. 2006;83-121.
66. Ebel B, Lemetais G, Beney L, Cachon R, Sokol H, Langella P, Gervais P. Impact of Probiotics on E. J. Quinto et al. 1773 risk factors for cardiovascular diseases. A Review. *Critical Reviews in Food Science and Nutrition*. 2014;54:175-189. Available:<http://dox.doi.org/10.1080/10408398.2011.57931>
67. Isolauri E, Joensuu J, Suomalainen H, Luomala M, Vesikari T. Improved immunogenicity of oral D x RRV reassortant rotavirus vaccine by Lactobacillus casei GG. *Vaccine*. 1995;13:310-312. Available:[http://dx.doi.org/10.1016/0264-410X\(95\)93319-5](http://dx.doi.org/10.1016/0264-410X(95)93319-5)
68. Ishikawa H, Akedo I, Umesaki Y, Tanaka R, Imaoka A, Otani T. Randomized controlled trial of the effect of Bifidobacteria-fermented milk on ulcerative colitis. *Journal of the American College of Nutrition*. 2003;22:56-63. Available:<http://dx.doi.org/10.1080/07315724.2003.10719276>
69. Kruis W, Fric P, Pokrotnieks J, Lukas M, Fixa B, Kascak M, Kamm MA, Weismuller J, Beglinger C, Stolte M, Wolff C, Schulze J. Maintaining remission of ulcerative colitis with the probiotic *Escherichia coli* Nissle 1917 Is as Effective as with Standard Mesalazine. *Gut*. 2004;53: 1617-1623. Available:<http://dx.doi.org/10.1136/gut.2003.037747>
70. McFarland LV, Surawicz CM, Greenberg RN, Fekety R, Elmer GW, Moyer KA, Melcher SA, Bowen KE, Cox JL, Noorani Z, Harrington G, Rubin M, Greenwald D. A randomized placebo-controlled trial of *Saccharomyces boulardii* in combination with standard antibiotics for clostridium difficile disease. *JAMA*. 1994;271: 1913-1918. Available:<http://dx.doi.org/10.1001/jama.1994.03510480037031>
71. Nista EC, Candelli M, Cremonini F, Cazzato IA, Zocco MA, Franceschi F, Cammarota G, Gasbarrini G, Gasbarrini A. *Bacillus clausii* therapy to reduce side-effects of anti-helicobacter pylori treatment: Randomized, double-blind, placebo controlled trial. *Alimentary Pharmacology & Therapeutics*. 2004;20:1181-1188.

- Available:<http://dx.doi.org/10.1111/j.1365-2036.2004.02274.x>
72. Wang YW, Jones PJH. Conjugated linoleic acid and obesity control: Efficacy and mechanisms. *International Journal of Obesity and Related Metabolic Disorders*. 2004;28:941-955.
Available:<http://dx.doi.org/10.1038/sj.ijo.0802641>
 73. Szajewska H, Ruszczyński M, Radzikowski A. Probiotics in the prevention of antibiotic-associated diarrhea in children: A meta-analysis of randomized controlled trials. *Journal of Pediatrics*, 2006;149:367-372.
Available:<http://dx.doi.org/10.1016/j.jpeds.2006.04.053>
 74. de Vrese M, Stegelmann A, Richter B, Fenselau S, Laue C, Schrezenmeir J. Probiotics—compensation for lactase insufficiency. *American Journal of Clinical Nutrition*. 2001;73:421S-429S.
 75. Lucas A, Cole TJ. Breast milk and neonatal necrotising enterocolitis. *The Lancet*. 1990;336:1519-1523.
Available:[http://dx.doi.org/10.1016/0140-6736\(90\)93304-8](http://dx.doi.org/10.1016/0140-6736(90)93304-8)
 76. Gewolb IH, Schwalbe RS, Taciak VL, Harrison TS, Panigrahi P. Stool microflora in extremely low birthweight infants. *Archives of Disease in Childhood Fetal Neonatal*. 1999;80:F167-F173.
Available:<http://dx.doi.org/10.1136/fn.80.3.F167>
 77. Reid G, Jass J, Sebulsky MT, McCormick JK. Potential uses of probiotics in clinical practice. *Clinical Microbiology Reviews*. 2003;16:658-672.
Available:<http://dx.doi.org/10.1128/CMR.16.4.658-672.2003>
 78. Hoyos AB. Reduced incidence of necrotizing enterocolitis associated with enteral administration of *Lactobacillus acidophilus* and *Bifidobacterium infantis* to neonates in an intensive care unit. *International Journal of Infectious Diseases*. 1999;3:197-202.
Available:[http://dx.doi.org/10.1016/S1201-9712\(99\)90024-3](http://dx.doi.org/10.1016/S1201-9712(99)90024-3)
 79. Caplan MS, Jilling T. Neonatal necrotizing enterocolitis: Possible role of probiotic supplementation. *Journal of Pediatric Gastroenterology and Nutrition*. 2000;30:S18-S22.
Available:<http://dx.doi.org/10.1097/00005176-2000040002-00004>
 80. Rohan T, Wainwright L. Does administering probiotic treatment to infants under 1500 g decrease the incidence of necrotising enterocolitis? A systematic literature review. *Journal of Neonatal Nursing*. 2014;2037-42.
Available:<http://dx.doi.org/10.1016/j.jnn.2013.04.007>
 81. Korterink JJ, Ockeloen L, Benninga MA, Tabbers MM, Hilbink M, Deckers-Kocken, JM. Probiotics for childhood functional gastrointestinal disorders: A systematic review and meta-analysis. *Acta Paediatrica*. 2014;103:365-372.
Available:<http://dx.doi.org/10.1111/apa.12513>
 82. de Silva D, Geromi M, Halken S, Host A, Panesar SS, Muraro A, Werfel T, Hoffmann-Sommergruber K, Roberts G, Cardona V, Dubois AEJ, Poulsen LK, Van Ree R, Vlieg-Boerstra B, Agache I, Grimshaw K, O'Mahony L, Venter C, Arshad SH, Sheikh A. On behalf of the eacaci food allergy and anaphylaxis guidelines group Primary Prevention of Food Allergy in Children and Adults: Systematic Review. *Allergy*. 2014;69:581-589.
Available:<http://dx.doi.org/10.1111/all.12334>
 83. Redman MG, Ward EJ, Phillips RS. The efficacy and safety of probiotics in people with cancer: A systematic review. *Annals of Oncology*. 2014;1-11.
Available:<http://dx.doi.org/10.1093/annonc/mdl106>
 84. Kunz AN, Noel JM, Fairchok MP. Two cases of *Lactobacillus* bacteremia during probiotic treatment of short gut syndrome. *Journal of Pediatric Gastroenterology and Nutrition*. 2004;38:457-458.
Available:<http://dx.doi.org/10.1097/00005176-200404000-00017>
 85. Land MH, Rouster-Stevens K, Woods CR, Cannon ML, Cnota J, Shetty AK. *Lactobacillus* Sepsis E. J. Quinto et al. 1774 associated with probiotic therapy. *Pediatrics*. 2005;115:178-181.
Available:<http://dx.doi.org/10.1542/peds.2004-2137>
 86. Klare I, Konstabel C, Werner G, Huys G, Vankerckhoven V, Kahlmeter G,

- Hildebrandt B, Müller-Bertling S, Witte W, Goossens H. Antimicrobial susceptibilities of *Lactobacillus*, *Pediococcus* and *Lactococcus* human isolates and cultures intended for probiotic or nutritional use. *Journal of Antimicrobial Chemotherapy*. 2007;59:900-912.
Available:<http://dx.doi.org/10.1093/jac/dkm035>
87. Korhonen JM, Van Hoek AH, Saarela M, Huys G, Tosi L, Mayrhofer S, Wright AV. Antimicrobial susceptibility of *Lactobacillus rhamnosus*. *Beneficial Microbes*. 2010;1: 75-80.
Available:http://dx.doi.org/10.3920/BM2009_0002 E. J. Quinto et al. 1775
88. National Cancer Institute (2010) Common Terminology Criteria for Adverse Events, Version 4.0.
Available:http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf
89. Bermúdez-Humarán LG, Kharrat P, Chatel JM, Langella P. Lactococci and Lactobacilli as mucosal delivery vectors for Therapeutic Proteins and DNA Vaccines. *Microbial Cell Factories*. 2011;10:S4.
Available:<http://dx.doi.org/10.1186/1475-2859-10-S1-S4>
90. Cotter PD, Ross RP, Hill C. Bacteriocins—A viable alternative to antibiotics? *Nature Reviews Microbiology*. 2013;11:95-105.
Available:<http://dx.doi.org/10.1038/nrmicro2937>
91. Hurst A. Nisin. *Advances in Applied Microbiology*. 1981;27:85-123.
Available:[http://dx.doi.org/10.1016/S0065-2164\(08\)70342-3](http://dx.doi.org/10.1016/S0065-2164(08)70342-3)
92. Vasudha S, Mishra HN. *International Food Research Journal*. 2012;20(1):7-15 (2013).
Available:<http://www.ifrj.upm.edu.my>
93. Atuma C, Strugala V, Allen A, Holm L. The Adherent gastrointestinal mucus gel layer: Thickness and physical state *in Vivo*. *American Journal Physiology Gastrointestinal Liver Physiology*. 2001;280:G922-G929.
94. Johansson ME, Phillipson M, Petersson J., Velcich A, Holm L, Hansson GC. The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of bacteria. *Proceedings of the National Academy of Sciences of the United States of America*. 2008;105:15064-15069.
Available:<http://dx.doi.org/10.1073/pnas.0803124105>
95. Troost FJ, van Baarlen P, Lindsey P, Kodde A, de Vos WM, Kleerebezem M, Brummer RJ. Identification of the transcriptional response of human intestinal mucosa to *Lactobacillus plantarum* WCFS1 *in Vivo*. *BMC Genomics*. 2008;9:374.
Available:<http://dx.doi.org/10.1186/1471-2164-9-374>
96. van Baarlen P, Troost FJ, van Hemert S, van der Meer C, de Vos WM, de Groot PJ, Hooiveld GJ, Brummer RJ, Kleerebezem M. Differential NF-KappaB pathways induction by *Lactobacillus plantarum* in the duodenum of healthy humans correlating with immune tolerance. *Proceedings of the National Academy of Sciences of the United States of America*. 2009;106: 2371-2376.
Available:<http://dx.doi.org/10.1073/pnas.0809919106>
97. Wells JM. Immunomodulatory Mechanisms of Lactobacilli. *Microbial Cell Factories*. 2011;10:S17.
Available:<http://dx.doi.org/10.1186/1475-2859-10-S1-S17>
98. Davis C. Enumeration of probiotic strains: Review of culture-dependent and alternative techniques to quantify viable bacteria. *Journal of Microbiological Methods*. 2014;103:9-17.
Available:<http://dx.doi.org/10.1016/j.mimet.2014.04.012>
99. Kalliomaki M, Salminen S, Arvilommi H, Kero P, Koskinen P, Isolauri E. Probiotics in primary prevention of atopic disease: A randomised placebo-controlled trial. *The Lancet*. 2001;357:1076-1079.
Available:[http://dx.doi.org/10.1016/S0140-6736\(00\)04259-8](http://dx.doi.org/10.1016/S0140-6736(00)04259-8)
100. Kalliomaki M, Salminen S, Poussa T, Arvilommi H, Isolauri E. Probiotics and prevention of atopic disease: 4-Year follow-up of a randomised placebo-controlled trial. *The Lancet*. 2003;361: 1869-1871.
Available:[http://dx.doi.org/10.1016/S0140-6736\(03\)13490-3](http://dx.doi.org/10.1016/S0140-6736(03)13490-3)
101. Tenover FC. Mechanisms of antimicrobial resistance in bacteria. *American Journal of Medicine*. 2006;119:S3-S10.
Available:<http://dx.doi.org/10.1016/j.amjmed.2006.03.011>
102. D'Aimmo MR, Modesto M, Biavati B. Antibiotic resistance of lactic acid bacteria and *Bifidobacterium* Spp. isolated from

- dairy and pharmaceutical products. International Journal of Food Microbiology. 2007;115:35-42.
Available:<http://dx.doi.org/10.1016/j.ijfoodmicro.2006.10.003>
103. Brooker BE. Imaging food systems by confocal scanning laser microscopy. In: Dickinson, E., Ed., *New Physico-Chemical Techniques for the Characterization of Complex Food Systems*, Blackie Academic and Profession, London. 1995;43-68.
 104. Heertje I, van der Vlist P, Blonk JCG, Hendrickx HAC, Brackenhof GJ. Confocal scanning laser microscopy in food research: Some observations. *Food Microstructure*. 1987;6:115-120.
 105. Auty MAE, Gardinere GC, Mc Breaty SJ, O'Sullivan EO, Muerill DM, Collins JK, Fitzgerald GJ, Stanton C, Ross RP. Direct *in situ* viability assessment of bacteria in probiotic dairy products using viability staining in conjunction with confocal scanning laser microscopy. *Applied and Environmental Microbiology*. 2001;67:420-425.
 106. Villarreal MLM, Padiha M, Vieira ADS, de Melo Franco BDG, Martinez RCR, Saad SMI. Advantageous direct quantification of viable closely related probiotics in petisuisse cheeses under *in vitro* gastrointestinal conditions by Propidium Monoazide-qPCR. *PLoS ONE*. 2013;8:e82102.
Available:<http://dx.doi.org/10.1371/journal.pone.0082102>
 107. Huls JHH, V., Havenaar R. Probiotics and health in man and animal. *J. Chem. Tech. Biotechnol*. 1991;51:562-567.
 108. Enumeration of Probiotic Strains: Review of Culture-Dependent and Alternative Techniques to Quantify Viable Bacteria. (PDF Download Available).
Available:https://www.researchgate.net/publication/262231148_Enumeration_of_Probiotic_Strains_Review_of_Culture-Dependent_and_Alternative_Techniques_to_Quantify_Viable_Bacteria
[Accessed Jan 06 2018]
 109. Nogva HK, Drømtorp SM, Nissen H, Rudi K. Ethidium Monoazide for DNA-Based Differentiation of Viable and Dead Bacteria by 5'-Nuclease PCR. *BioTechniques*. 2003;34:804-808, 810, 812-813.
 110. CosmeticsDesign.com.
Available:<http://www.cosmeticsdesign.com/Formulation-Science>
(Accessed December 10, 2009)
 111. de Vrese M, Rautenberg P, Laue C, Koopmans M, Herremans T, Schrezenmeir J. Probiotic bacteria stimulate virus-specific neutralizing antibodies following a booster polio vaccination. *European Journal of Nutrition*. 2005;44:406-413.
Available:<http://dx.doi.org/10.1007/s00394-004-0541-8>
 112. Paineau D, Carcano D, Leyer G, Darquy S, Alyanakian MA, Simoneau G, Bergmann JF, Brassart D, Bornet F, Ouwehand AC. Effects of seven potential probiotic strains on specific immune responses in healthy adults: A double-blind, randomized, controlled trial. *FEMS Immunology and Medical Microbiology*. 2008;53:107-113.
Available:<http://dx.doi.org/10.1111/j.1574-695X.2008.00413.x>
 113. Wang X, Jiang Y, Wang YW, Huang MT, Ho CT, Huang Q. Enhancing antiinflammation activity of curcumin through O/W nanoemulsions. *Food Chem*. 2008;108(2):419-424. [PubMed]
 114. Costa C. Nanocomposites to extend the shelf life of ready to use fruit and vegetables 14th Workshop on the Developments in the Italian PhD Research on Food Science Technology and Biotechnology – University of Sassari, Oristano; 2009.
Available:<http://www.consorziouno.it/consorzio/export/sites/default/Workshop/Contributi/Anno/Costa.pdf>
(Accessed February 26, 2010)
 115. Fukao M, Yajima N. Assessment of Antibiotic Resistance in Probiotic Lactobacilli. In: Pana, M., Ed., *Antibiotic Resistant Bacteria—A Continuous Challenge in the New Millennium*, InTech; 2012.
Available:<http://cdn.intechopen.com/pdfs/34707.pdf>
 116. Patel AR, Shah NP, Prajapati JB. Antibiotic resistance profile of lactic acid bacteria and their implication in food chain. *World Journal of Dairy & Food Sciences*. 2012;7:202-211.
Available:<http://dx.doi.org/10.5829/idosi.wjdfs.2012.7.2.1113>
 117. Flórez AB, Danielsen M, Korhonen J, Zyckal J, von Wright A, Bardowski J, Mayo B. Antibiotic survey of *Lactococcus lactis* strains to six antibiotics by etest and

- establishment of new susceptibility-resistance cut-off values. *Journal of Dairy Research*. 2007;74:262-268.
Available:<http://dx.doi.org/10.1017/S0022029907002543>
118. Wang X, Jiang Y, Wang YW, Huang Q. ACS Symposium Series. Micro/Nanoencapsulation of Active Food Ingredients. Enhancing stability and oral bioavailability of polyphenols using nanoemulsions. 1007;198–212. Chapter 13. Chapter. [Cross Ref]
119. Relkin P, Yung JM, Kalnin D, Ollivon M. Structural behaviour of lipid droplets in protein-stabilized nano-emulsions and stability of α -tocopherol. *Food Biophys*. 2008;3(2):163–168.

© 2018 Kumar et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:
The peer review history for this paper can be accessed here:
<http://prh.sdiarticle3.com/review-history/24457>